Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer

被引:311
作者
Chlebowski, Rowan T. [1 ]
Johnson, Karen C. [2 ]
Kooperberg, Charles [3 ]
Pettinger, Mary [3 ]
Wactawski-Wende, Jean [4 ]
Rohan, Tom [5 ]
Rossouw, Jacques [6 ]
Lane, Dorothy [7 ]
O'Sullivan, Mary Jo [8 ]
Yasmeen, Shagufta [9 ]
Hiatt, Robert A. [10 ]
Shikany, James M. [11 ]
Vitolins, Mara [12 ]
Khandekar, Janu [13 ]
Hubbell, F. Allan [14 ]
机构
[1] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA
[2] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[4] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA
[5] Albert Einstein Coll Med, Bronx, NY 10467 USA
[6] NHLBI, Bethesda, MD 20892 USA
[7] SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA
[8] Univ Miami, Dept Obstet & Gynecol, Miami, FL USA
[9] Univ Calif Davis, Dept Med, Sacramento, CA 95817 USA
[10] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[11] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL USA
[12] Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA
[13] Northwestern Univ, Dept Med, Chicago, IL 60611 USA
[14] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2008年 / 100卷 / 22期
基金
美国国家卫生研究院;
关键词
D O I
10.1093/jnci/djn360
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although some observational studies have associated higher calcium intake and especially higher vitamin D intake and 25-hydroxyvitamin D levels with lower breast cancer risk, no randomized trial has evaluated these relationships. Postmenopausal women (N = 36 282) who were enrolled in a Women's Health Initiative clinical trial were randomly assigned to 1000 mg of elemental calcium with 400 IU of vitamin D-3 daily or placebo for a mean of 7.0 years to determine the effects of supplement use on incidence of hip fracture. Mammograms and breast exams were serially conducted. Invasive breast cancer was a secondary outcome. Baseline serum 25-hydroxyvitamin D levels were assessed in a nested case-control study of 1067 case patients and 1067 control subjects. A Cox proportional hazards model was used to estimate the risk of breast cancer associated with random assignment to calcium with vitamin D-3. Associations between 25-hydroxyvitamin D serum levels and total vitamin D intake, body mass index (BMI), recreational physical activity, and breast cancer risks were evaluated using logistic regression models. Statistical tests were two-sided. Invasive breast cancer incidence was similar in the two groups (528 supplement vs 546 placebo; hazard ratio = 0.96; 95% confidence interval = 0.85 to 1.09). In the nested case-control study, no effect of supplement group assignment on breast cancer risk was seen. Baseline 25-hydroxyvitamin D levels were modestly correlated with total vitamin D intake (diet and supplements) (r = 0.19, P < .001) and were higher among women with lower BMI and higher recreational physical activity (both P < .001). Baseline 25-hydroxyvitamin D levels were not associated with breast cancer risk in analyses that were adjusted for BMI and physical activity (P-trend = .20). Calcium and vitamin D supplementation did not reduce invasive breast cancer incidence in postmenopausal women. In addition, 25-hydroxyvitamin D levels were not associated with subsequent breast cancer risk. These findings do not support a relationship between total vitamin D intake and 25-hydroxyvitamin D levels with breast cancer risk.
引用
收藏
页码:1581 / 1591
页数:11
相关论文
共 46 条
[1]   Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer - results of a large case-control study [J].
Abbas, Sascha ;
Linseisen, Jakob ;
Slanger, Tracy ;
Kropp, Silke ;
Mutschelknauss, Elke Jonny ;
Flesch-Janys, Dieter ;
Chang-Claude, Jenny .
CARCINOGENESIS, 2008, 29 (01) :93-99
[2]   Serum calcium and breast cancer risk: results from a prospective cohort study of 7,847 women [J].
Almquist, Martin ;
Manjer, Jonas ;
Bondeson, Lennart ;
Bondeson, Anne-Greth .
CANCER CAUSES & CONTROL, 2007, 18 (06) :595-602
[3]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[4]  
[Anonymous], DIET REF INT RISK AS
[5]  
Bertone-Johnson ER, 2007, NUTR REV, V65, P459, DOI 10.1111/j.1753-4887.2007.tb00271.x
[6]   Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer [J].
Bertone-Johnson, ER ;
Chen, WY ;
Holick, MF ;
Hollis, BW ;
Colditz, GA ;
Willett, WC ;
Hankinson, SE .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (08) :1991-1997
[7]   Intake of selected foods and nutrients and breast cancer risk: An age- and menopause-specific analysis [J].
Braga, C ;
LaVecchia, C ;
Negri, E ;
Franceschi, S ;
Parpinel, M .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1997, 28 (03) :258-263
[8]   American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition [J].
Chlebowski, RT ;
Col, N ;
Winer, EP ;
Collyar, DE ;
Cummings, SR ;
Vogel, VG ;
Burstein, HJ ;
Eisen, A ;
Lipkus, I ;
Pfister, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3328-3343
[9]  
Colston KW, 2006, ANTICANCER RES, V26, P2573
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187